Rheumatoid Arthritis
New Frontiers in Pathogenesis and Treatment
Published in August 2000
Book
Hardback
598 pages
978-0-19-262972-2 (ISBN)
Description
The old saying "we now know all about rheumatoid arthritis except what causes it and how to cure it" may still be true, but we certainly have a number of clues. This book presents the cutting edge of developments in etiology, mechanisms of inflammation, disease manifestations and management of this common, crippling disease. Therapy for RA has traditionally been with non-steroid anti-inflammatory drugs, progressing to second-line drugs, but this has not been effective in preventing erosion of bone and symptoms. Rapid advances in knowledge have led to new concepts in the mechanisms of the disease and new possibilities for treatment. This book deals with the This book is intended for clinical specialist and research rheumatologists. Immunologists working in areas of research in rheumatology.
Reviews / Votes
...breaks new ground... a scholarly, thoroughly academic monograph for serious students of the disease whether as scientific investigators or clinicians... unique, majestic tribute to the immense effort now directed at unravelling the mysteries of the field. Scandinavian Journal of Rheumatology This book demonstrates the enormous achievement in the knowledge of pathogenesis that has... transformed practice in targeted treatments... it gives to physicians an intellectual and modern pathway of looking at rheumatoid arthritis. Marco Matucci-Cerinic, University of Florence, ItalyMore details
Language
English
Place of publication
Oxford
United Kingdom
Target group
College/higher education
Professional and scholarly
Illustrations
colour and b&w illustrations
Dimensions
Height: 276 mm
Width: 219 mm
Weight
1955 gr
ISBN-13
978-0-19-262972-2 (9780192629722)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Classification
Other editions
New editions
Gary S. Firestein | Gabriel Panayi | Frank Wollheim
Rheumatoid Arthritis
Book
07/2006
2nd Edition
Oxford University Press
€390.61
Article exhausted; check different version
Content
SECTION ONE: ETIOLOGY; 1. Current Perspectives on the genetics of rheumatoid arthritis; 2. Epidemiology of rheumatoid arthritis; 3. Infection in the pathogenesis of rheumatoid arthritis; 4. Experimental Models for rheumatoid arthritis; SECTION TWO: MECHANISMS OF INFLAMMATION; 5. Examination of the synovium and synovial fluid; 6. The Role of macrophages in rheumatoid arthritis; 7. The Role of T lymphocytes in rheumatoid arthritis; 8. The role of neutrophils in rheumatoid arthritis; 9. The role of fibroblast-like synoviocytein rheumatoid arthritis; 10. Adhesion, migration and cell trafficking; 11. Cytokine networks; 12. Apoptosis in rheumatoid arthritis: Cause or Consequence; 13. Rheumatoid Factor; 14. Mehanisms of joint destruction; 15. Pain mechanisms in rheumatoid arthritis; SECTION THREE: CLINICAL ASPECTS; 16. Rheumatoid arthritis: clinical picture and its variants; 17. Extra-articular features of rheumatoid arthritis; 18. The neuroendocrine axis in rheumatoid arthritis; 19. Imaging; 20. Outcome and mortality; 21. Molecular markers for assessment of cartilage damage in rheumatoid arthritis; SECTION FOUR: DRUG THERAPY; 22. NSAIDs and analgesics; 23. Systemic glucocorticoids in rheumatoid arthritis; 24. Methotrexate; 25. Gold, antimalarials, sulphasalazine and other DMARDs; 26. Intra-articular therapy; 27. Combination therapy for rheumatoid arthritis; SECTION FIVE: NON-DRUG THERAPY; 28. The Impact of physiotherapy; 29. Occupational therapy and assistive technology; 30. Diets; 31. Psychological and social aspects; 32. Patient education; 33. Non-drug management of chronic pain; 34. Health economics; SECTION SIX: SURGICAL THERAPY; 35. Large joints and feet; 36. The hand; 37. The cervical spine; 38. Medical synovectomy (synoviorthesis); SECTION SEVEN: FRONTIERS OF THERAPY; 39. Anticytokine therapy: TNF Inhibitors and other novel approaches; 40. The design of clinical trials; 41. Anti-T lymphocyte therapies; 42. Antimacrophage therapies; 43. Inhibition of matrix metalloproteinases in rheumatoid arthritis; 44. Small molecule inhibitors of signal transduction